Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
150 hedge funds and large institutions have $2.22B invested in Aegerion Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 36 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
9% more call options, than puts
Call options by funds: $124M | Put options by funds: $113M
2% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 55
3% less funds holding
Funds holding: 154 → 150 (-4)
11% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 36
14% less capital invested
Capital invested by funds: $2.59B → $2.22B (-$373M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$116M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$41.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.6M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$36M |
| 5 |
HM
HealthCor Management
New York
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$144M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$40.6M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$24.5M |
| 4 |
AA
Antipodean Advisors
New York
|
-$22.8M |
| 5 |
CCI
Columbus Circle Investors
|
-$21.7M |
AEGR Hedge Fund Activity: Q4 2013 in Review
150 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q4 2013, worth a combined $2.22B — down 14% from $2.59B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AEGR and 32 opened new positions — a net loss of 4 holders — while 55 trimmed existing stakes and 56 added.
The largest buyer was Fidelity Investments, adding an estimated $116M. The largest seller was Perceptive Advisors, cutting an estimated $144M.
- 150 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q4 2013, down from 154 in Q3 2013.
- Funds reported $2.22B of Aegerion Pharmaceuticals stock for Q4 2013, down 14% quarter-over-quarter.
- 32 funds opened new Aegerion Pharmaceuticals positions in Q4 2013 and 36 closed out, a net change of -4 holders.
- The largest Aegerion Pharmaceuticals buyer in Q4 2013 was Fidelity Investments, an estimated $116M added.
- The largest Aegerion Pharmaceuticals seller in Q4 2013 was Perceptive Advisors, an estimated $144M sold.
Based on aggregated 13F filings for Q4 2013.